Combination Chemotherapy in Breast Cancer: A 15-Year Perspective
نویسندگان
چکیده
منابع مشابه
Paclitaxel-based combination chemotherapy for breast cancer.
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration...
متن کاملMGBG–cisplatin combination chemotherapy against breast cancer
Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, representing 14% of female cancer deaths [1], about 4,500 new cases being detected each year in Portugal. In the present study, the compound metylglyoxal bis(guanylhydrazone) (MGBG) [2], an inhibitor of S-adenosylL-methionine descarboxylase (SAMdc), was investigated as a potencial anti-cance...
متن کاملIllness perception of breast cancer in affected women undergoing chemotherapy
Abstract Background: The aim of this study was to investigate the various aspects of illness perceptions about breast cancer in affected patients. Methods: A cross-sectional study enrolled 140 patients with breast cancer in their chemotherapy period within 14 months. The revised Illness Perception Questionnaire (revised IPQ) was used to assess the disease representations of breast cancer. The ...
متن کاملIntroduction. Single-agent or combination chemotherapy in metastatic breast cancer.
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملSingle-Agent or Combination Chemotherapy in Metastatic Breast Cancer
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Investigation
سال: 1985
ISSN: 0735-7907,1532-4192
DOI: 10.3109/07357908509039800